High-Risk Merchant Accounts

LegitScript Now Certifies Telehealth Sites That Offer BPC-157 Under HHS Conditions

LegitScript's November 2 update lets telehealth sites offering BPC-157 and five other peptides earn certification if they meet HHS's 503A conditions, but blends, pens, 503B products and state bans such as Kentucky's still stand in the way.

Pharmacist in a white coat weighs powder on a brass balance as a man in a tweed suit writes on a clipboard beside amber bottles.
On a snowy morning in a pharmacy back room, a pharmacist weighs powder on a brass balance while a man in a tweed suit takes notes on a clipboard, the kind of compounding review peptide programs now face.

LegitScript, the company whose certification many ad platforms and payment providers look for before working with online pharmacies and telehealth sites, changed its review rules on November 2 so that offering BPC-157 and five other compounded peptides no longer counts against a merchant by itself. In a guidance post published that day, LegitScript said offering one of the six “should not, by itself, prevent a merchant from achieving certification,” provided the product meets the conditions of the U.S. Department of Health and Human Services (HHS) enforcement discretion policy for 503A compounding and every other certification standard.

The six peptides are BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-C. Before the change, a telehealth brand selling any of them faced a barrier to the seal. Now its file will be judged on the exact ingredient, the pharmacy making it and the paperwork behind both.

The HHS policy behind the change

HHS released its “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” on October 28, and the Federal Register notice followed on October 30. The policy says the U.S. Food and Drug Administration (FDA) does not intend to take specified enforcement action against qualifying 503A pharmacies and physician compounders that use the six peptides under ten conditions. It does not approve the peptides or add them to FDA’s 503A bulks list. EC4IM covered the policy’s terms in detail in its November 11 report.

LegitScript stresses that November 2 is its own implementation date, separate from the dates HHS issued and published the policy. It also notes that FDA can revise or withdraw the policy at any time.

What LegitScript will look at

LegitScript said its review will consider the specific ingredient, formulation, route of administration, compounding facility and supply chain. Its FAQ lists the documents applicants should be ready to supply:

  • Formulation, ingredient form and route of administration
  • The compounding facility
  • Manufacturer and sourcing documentation
  • Certificates of analysis
  • Labeling
  • Delivery-device details

Each peptide is covered only in one chemical form and by certain routes. BPC-157 acetate qualifies for subcutaneous, intramuscular, oral and topical use. TB-500, Epitalon and MOTS-C, all acetates, qualify only as subcutaneous or intramuscular injections. Semax free base is limited to intranasal use, and KPV acetate to topical and oral use. Oral products also need documentation that the specific formulation reaches adequate bioavailability in humans.

Where certification still stops

LegitScript’s post draws several firm lines:

  • Single ingredient only. LegitScript reads the HHS policy as requiring a single active ingredient. Its FAQ says blends such as BPC-157 with TB-500, or BPC-157 with semaglutide, do not qualify.
  • Syringes, not pens. The only delivery device allowed with the product is an FDA 510(k)-cleared syringe. LegitScript warns that clearance of another device, such as an injector pen, does not meet the condition.
  • 503A only. Outsourcing facilities registered under section 503B are not covered.
  • Other peptides. LegitScript says offering peptides or formulations that fall outside the policy, and are not otherwise eligible for 503A or 503B compounding, “remains a barrier to certification.”

Research-use-only sellers gain nothing from the change. The policy protects licensed compounders working from patient-specific prescriptions, and LegitScript tells businesses to make sure labels and marketing do not suggest that enforcement discretion means FDA approval. Certified merchants will also stay under monitoring. LegitScript says compliant peptide offerings will not draw certification enforcement action “solely” because of the peptides, while the rest of a merchant’s products and practices remain under review.

Certification is not ad or payment approval

LegitScript is direct on this point. Its FAQ answers “No” to whether certification guarantees a business can advertise or process payments for these products, and the post says platform policies “may not align with LegitScript’s timeline.” Ad networks, processors, acquirers and card brands set their own rules. EC4IM reported last week on Google’s move to accept NABP accreditation for telemedicine ad certification, another reminder that each platform runs its own process.

Kentucky shows state law still decides

Federal enforcement discretion does not override state pharmacy law, and one state has already said so in writing. On November 18 the Kentucky Board of Pharmacy voted to enforce its compounding regulation, 201 KAR 2:076, as written and to refuse waivers for the six peptides. Its compliance alert dated November 19 tells pharmacies not to compound the peptides for human use and not to dispense or ship them to patients or practitioners in Kentucky, including from nonresident pharmacies the board permits.

For a telehealth brand that sells nationally, that turns a federal green light into a state-by-state shipping question. A peptide program would need a way to keep Kentucky addresses out of its order flow, and processors reviewing multistate peptide programs, including specialty providers such as Organic Payment Gateways, may ask how that block works. EC4IM has also covered the Mississippi Board of Pharmacy’s October position on research-grade peptides.

Pharmacy groups are pressing too. The pharmacists’ association ASHP and the American College of Clinical Pharmacy said on November 18 that they had urged HHS to aggressively enforce the policy and asked FDA to monitor online marketplaces and the gray market and to clarify how it will use safety signals from adverse event reports to adjust or rescind it.

A narrower opening than the headlines suggest

LegitScript’s November 2 update lets a telehealth site offering BPC-157 or the other five covered peptides earn certification, but only for single-ingredient products in the listed forms and routes, made by a qualifying 503A pharmacy or physician compounder with full sourcing records, and packaged with a cleared syringe when a device is included. The seal does not settle advertising or payment approval, and it does not clear the products in states such as Kentucky, whose pharmacy board has barred compounding them and shipping them to patients there. With pharmacy groups pressing for tighter enforcement and FDA free to change course, any peptide program built on this opening also needs a plan for the day the rules shift again.

Sources